Tiziana Life Sciences Ltd (TLSA)

$0.99 -0.02 (-2.18%)
Market Cap 128.53M
Revenue (ttm) 0.00
Net Income (ttm) -18.43M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 429,900
Avg Vol 621,764
Day's Range N/A - N/A
Shares Out 127.26M
Stochastic %K 6%
Beta 0.49
Analysts Sell
Price Target $9.00

Company Profile

Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R mono...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 20 7495 2379
Address:
14/15 Conduit Street, London, United Kingdom
weather
weather Sep. 1 at 11:01 AM
$TLSA this must be the best short controlled stock in the market- they do want they want with it !
1 · Reply
JuggernautRaider
JuggernautRaider Aug. 31 at 9:49 PM
$TNXP $TLSA $IMRX $ALT 💊 🧠 🍱 🧬 🧘‍♂️
0 · Reply
WHATABOUTSTOCKS
WHATABOUTSTOCKS Aug. 31 at 8:25 PM
$TLSA $OKYO $ACUT = all you need to know ;) worst management.
0 · Reply
WHATABOUTSTOCKS
WHATABOUTSTOCKS Aug. 31 at 8:24 PM
$TLSA will probably delay again ... and again!
1 · Reply
123fabio
123fabio Aug. 31 at 7:05 PM
$TLSA I can't wait to get rid of $TLSA. It's hands down the worst stock I've held in my portfolio since 2021, a total and constant disappointment.
2 · Reply
rp6577
rp6577 Aug. 31 at 4:40 PM
$TLSA added. Very much expecting a rally into the phase 2a data. Positive readout will then send it. Big pharma asked to see data first. Very likely a partnership will arise for phase 3 $XBI
1 · Reply
JuggernautRaider
JuggernautRaider Aug. 28 at 2:05 PM
$IXHL oh baby kangaroo 🦘 $TLSA $INM $CGTX 😲
0 · Reply
weather
weather Aug. 28 at 6:31 AM
$TLSA Beware the shorters are back in town
2 · Reply
Iceman89
Iceman89 Aug. 26 at 8:23 PM
$TLSA Only about a month left!
1 · Reply
JuggernautRaider
JuggernautRaider Aug. 26 at 7:57 PM
$CGTX @Biopharma15 @Biotech_Beast @Biopharma2021 @Proposition_Joe @PeteyUSA Owe I agree. I’ve quietly accumulated 10K shares of CGTX. Also buying up $VYGR and $TLSA Sell $TSLA it is a DOG 🐶 ⚡️ 🪦
1 · Reply
Latest News on TLSA
Tiziana Life Sciences Announces Poster Presentation on Phase 2a BANYAN Clinical Trial of Intranasal Foralumab at ALS Nexus 2026

Aug 24, 2026, 7:00 AM EDT - 8 days ago

Tiziana Life Sciences Announces Poster Presentation on Phase 2a BANYAN Clinical Trial of Intranasal Foralumab at ALS Nexus 2026

Tiziana Life Sciences CEO Ivor Elrifi purchases 321,423 shares

2026-08-06T13:16:44.000Z - 26 days ago

Tiziana Life Sciences CEO Ivor Elrifi purchases 321,423 shares

Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer

Aug 4, 2026, 7:00 AM EDT - 4 weeks ago

Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer

Tiziana Reports Reduction in Brain Inflammation in Third Multiple System Atrophy Patient Treated with Intranasal Foralumab

Jul 31, 2026, 7:00 AM EDT - 4 weeks ago

Tiziana Reports Reduction in Brain Inflammation in Third Multiple System Atrophy Patient Treated with Intranasal Foralumab

Tiziana Life Sciences chairman Gabriele Cerrone purchases 42,357 shares at 99c

2026-07-22T11:30:23.000Z - 5 weeks ago

Tiziana Life Sciences chairman Gabriele Cerrone purchases 42,357 shares at 99c

Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman

Jul 22, 2026, 7:00 AM EDT - 5 weeks ago

Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman

Tiziana Life Sciences doses last patient in intranasal foralumab trial

2026-06-25T11:20:37.000Z - 2 months ago

Tiziana Life Sciences doses last patient in intranasal foralumab trial

Tiziana Announces Last Patient Successfully Dosed in its Phase 2 INFORM-MS Trial

Jun 25, 2026, 7:00 AM EDT - 2 months ago

Tiziana Announces Last Patient Successfully Dosed in its Phase 2 INFORM-MS Trial

Tiziana Life Sciences chairman Gabriele Cerrone purchases 15,000 shares

2026-06-15T11:42:42.000Z - 2 months ago

Tiziana Life Sciences chairman Gabriele Cerrone purchases 15,000 shares

Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York

May 28, 2026, 7:00 AM EDT - 3 months ago

Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York

Tiziana fully enrolls Phase 2 placebo-controlled MS trial

2026-05-21T15:05:09.000Z - 3 months ago

Tiziana fully enrolls Phase 2 placebo-controlled MS trial

Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial

May 21, 2026, 11:00 AM EDT - 3 months ago

Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial

Tiziana Life Sciences announces updated intranasal foralumab data

2026-05-19T12:13:28.000Z - 3 months ago

Tiziana Life Sciences announces updated intranasal foralumab data

Tiziana Announces New Positive Clinical Data for Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis

May 19, 2026, 7:00 AM EDT - 3 months ago

Tiziana Announces New Positive Clinical Data for Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis

Tiziana Phase 2 trial for foralumab shows reduced brain inflammation

2026-05-14T13:46:05.000Z - 3 months ago

Tiziana Phase 2 trial for foralumab shows reduced brain inflammation

Tiziana Reports Reduced Brain Inflammation in Multiple System Atrophy Patients Treated with Intranasal Foralumab

May 14, 2026, 7:00 AM EDT - 3 months ago

Tiziana Reports Reduced Brain Inflammation in Multiple System Atrophy Patients Treated with Intranasal Foralumab

Tiziana Life announces publication of preclinical data in bioRxiv preprint

2026-04-16T12:01:24.000Z - 4 months ago

Tiziana Life announces publication of preclinical data in bioRxiv preprint

Tiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and Improves Cognitive Function

Apr 16, 2026, 7:00 AM EDT - 4 months ago

Tiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and Improves Cognitive Function

Tiziana Life Sciences Announces Late Breaking Poster Accepted for Presentation at the 7th World Parkinson Congress

Apr 14, 2026, 7:00 AM EDT - 5 months ago

Tiziana Life Sciences Announces Late Breaking Poster Accepted for Presentation at the 7th World Parkinson Congress

Tiziana Announces Data Showing Nasal Anti-CD3 Improves Cognition Associated with Aging

Apr 1, 2026, 7:00 AM EDT - 5 months ago

Tiziana Announces Data Showing Nasal Anti-CD3 Improves Cognition Associated with Aging

Tiziana Life Sciences announces new data on nasal foralumab

2026-02-25T12:25:15.000Z - 6 months ago

Tiziana Life Sciences announces new data on nasal foralumab

Tiziana Life Sciences Announces New Biomarker Data Showing Nasal Foralumab Downregulates CSF Inflammation, Upregulates Neuroprotective Pathways, and Correlates with Reduced Microglial Activation on PET Scans in na-SPMS Patients with PIRA

Feb 25, 2026, 7:00 AM EST - 6 months ago

Tiziana Life Sciences Announces New Biomarker Data Showing Nasal Foralumab Downregulates CSF Inflammation, Upregulates Neuroprotective Pathways, and Correlates with Reduced Microglial Activation on PET Scans in na-SPMS Patients with PIRA

Tiziana Life Sciences announces publication of intranasal foralumab results

2026-01-20T16:20:10.000Z - 8 months ago

Tiziana Life Sciences announces publication of intranasal foralumab results

Tiziana Life Sciences Announces the Peer-Reviewed Publication of Clinical Study Results for Intranasal Foralumab

Jan 20, 2026, 11:15 AM EST - 8 months ago

Tiziana Life Sciences Announces the Peer-Reviewed Publication of Clinical Study Results for Intranasal Foralumab

Tiziana Life Sciences Announces Closing of Oversubscribed $8.8 Million Registered Direct Offering of Ordinary Shares

Jan 16, 2026, 2:45 PM EST - 8 months ago

Tiziana Life Sciences Announces Closing of Oversubscribed $8.8 Million Registered Direct Offering of Ordinary Shares

Tiziana Life Sciences prices 6.4M shares at $1.25 in registered direct offering

2026-01-16T12:05:16.000Z - 8 months ago

Tiziana Life Sciences prices 6.4M shares at $1.25 in registered direct offering

Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $17.6 Million

Jan 16, 2026, 7:00 AM EST - 8 months ago

Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $17.6 Million

Tiziana Life Sciences to Present at the 9th Annual Neuroscience Innovation Forum During J.P. Morgan Healthcare Conference Week in San Francisco

Jan 9, 2026, 7:00 AM EST - 8 months ago

Tiziana Life Sciences to Present at the 9th Annual Neuroscience Innovation Forum During J.P. Morgan Healthcare Conference Week in San Francisco

Tiziana Life Sciences files annual safety report for intranasal foralumab

2025-12-29T13:15:44.000Z - 8 months ago

Tiziana Life Sciences files annual safety report for intranasal foralumab

Tiziana Files Annual Safety Report for Intranasal Foralumab with FDA

Dec 29, 2025, 8:00 AM EST - 8 months ago

Tiziana Files Annual Safety Report for Intranasal Foralumab with FDA

Tiziana Life Sciences Chairman raises stake to 36% with acquisition of shares

2025-12-19T16:05:39.000Z - 9 months ago

Tiziana Life Sciences Chairman raises stake to 36% with acquisition of shares

Tiziana Life Sciences Announces Acquisition of Shares by Executive Chairman

Dec 19, 2025, 11:00 AM EST - 9 months ago

Tiziana Life Sciences Announces Acquisition of Shares by Executive Chairman

Tiziana Life Sciences to Ring the Closing Bell at Nasdaq

Dec 17, 2025, 10:00 AM EST - 9 months ago

Tiziana Life Sciences to Ring the Closing Bell at Nasdaq

Tiziana Life Sciences doses first patient in Phase 2 Alzheimer’s trial

2025-12-17T13:50:17.000Z - 9 months ago

Tiziana Life Sciences doses first patient in Phase 2 Alzheimer’s trial

Tiziana Life Sciences Doses First Patient in Phase 2 Alzheimer's Clinical Trial

Dec 17, 2025, 8:45 AM EST - 9 months ago

Tiziana Life Sciences Doses First Patient in Phase 2 Alzheimer's Clinical Trial

Tiziana Life Sciences CEO Ivor Elrifi purchases 163,400 shares

2025-12-15T20:15:08.000Z - 9 months ago

Tiziana Life Sciences CEO Ivor Elrifi purchases 163,400 shares

Tiziana Life Sciences announces withdrawal of proposed public offering

2025-12-15T12:35:32.000Z - 9 months ago

Tiziana Life Sciences announces withdrawal of proposed public offering

Tiziana Life Sciences Announces Withdrawal of Proposed Public Offering

Dec 15, 2025, 7:30 AM EST - 9 months ago

Tiziana Life Sciences Announces Withdrawal of Proposed Public Offering

Tiziana Life Sciences to dose first patient in Phase 2 Alzheimer’s trial

2025-12-12T19:15:11.000Z - 9 months ago

Tiziana Life Sciences to dose first patient in Phase 2 Alzheimer’s trial

Tiziana Life Sciences to Dose First Patient in Phase 2 Alzheimer's Trial

Dec 12, 2025, 2:10 PM EST - 9 months ago

Tiziana Life Sciences to Dose First Patient in Phase 2 Alzheimer's Trial

Tiziana Life Sciences plans to spinout IL-6 asset into separate listed company

2025-12-02T12:05:39.000Z - 9 months ago

Tiziana Life Sciences plans to spinout IL-6 asset into separate listed company

Tiziana Life Sciences Plans to Spinout IL-6 Asset into Separate Listed Company

Dec 2, 2025, 7:00 AM EST - 9 months ago

Tiziana Life Sciences Plans to Spinout IL-6 Asset into Separate Listed Company

Tiziana Life announces Phase 2 foralumab study accepted into Healey ALS program

2025-11-25T13:40:48.000Z - 10 months ago

Tiziana Life announces Phase 2 foralumab study accepted into Healey ALS program

Tiziana Life Sciences Nasal Foralumab Phase 2 Clinical Trial Accepted into Healey ALS MyMatch Program

Nov 25, 2025, 8:30 AM EST - 10 months ago

Tiziana Life Sciences Nasal Foralumab Phase 2 Clinical Trial Accepted into Healey ALS MyMatch Program

Tiziana Life Sciences to Present at Jefferies Global Healthcare Conference

Nov 13, 2025, 8:30 AM EST - 10 months ago

Tiziana Life Sciences to Present at Jefferies Global Healthcare Conference

Tiziana Life Sciences to Present at BIO-Europe in Vienna, Highlighting Innovative Immunomodulation Therapy

Oct 29, 2025, 7:00 AM EDT - 10 months ago

Tiziana Life Sciences to Present at BIO-Europe in Vienna, Highlighting Innovative Immunomodulation Therapy

Tiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in Riyadh, Saudi Arabia

Sep 30, 2025, 8:30 AM EDT - 1 year ago

Tiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in Riyadh, Saudi Arabia

Tiziana Life Sciences Announces Poster Presentation on Intranasal Foralumab Clinical Trial at the 41st ECTRIMS Congress

Sep 24, 2025, 8:30 AM EDT - 1 year ago

Tiziana Life Sciences Announces Poster Presentation on Intranasal Foralumab Clinical Trial at the 41st ECTRIMS Congress

Department of Defense Awards Grant to Advance Tiziana Life Sciences Intranasal Anti-CD3 Therapy for Spinal Cord Injury

Sep 15, 2025, 8:00 AM EDT - 1 year ago

Department of Defense Awards Grant to Advance Tiziana Life Sciences Intranasal Anti-CD3 Therapy for Spinal Cord Injury

Tiziana Life Sciences Announces Purchase of Shares by Chairman

Sep 5, 2025, 8:30 AM EDT - 1 year ago

Tiziana Life Sciences Announces Purchase of Shares by Chairman

Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy

Aug 14, 2025, 8:30 AM EDT - 1 year ago

Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy

FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy

Aug 11, 2025, 9:00 AM EDT - 1 year ago

FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy

Tiziana Life Sciences Announces Immunologic Analysis of Nasal Foralumab in Moderate Alzheimer's Patient

Jul 21, 2025, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces Immunologic Analysis of Nasal Foralumab in Moderate Alzheimer's Patient

Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center

Jun 13, 2025, 10:30 AM EDT - 1 year ago

Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center

Tiziana Life Sciences to Present at the Bio International Convention

Jun 13, 2025, 8:30 AM EDT - 1 year ago

Tiziana Life Sciences to Present at the Bio International Convention

Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer's Disease

May 23, 2025, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer's Disease

Journal of Clinical Nuclear Medicine Publishes Results of Tiziana's Nasal Foralumab in Study Treating Moderate Alzheimer's Disease

May 15, 2025, 8:00 AM EDT - 1 year ago

Journal of Clinical Nuclear Medicine Publishes Results of Tiziana's Nasal Foralumab in Study Treating Moderate Alzheimer's Disease

Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab

May 9, 2025, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab

Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis

May 6, 2025, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis

Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial

Apr 23, 2025, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial

Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial

Apr 2, 2025, 8:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial

Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial

Mar 25, 2025, 8:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial

Tiziana Life Sciences to Present at the 37th Annual Roth Conference

Mar 17, 2025, 8:00 AM EDT - 1 year ago

Tiziana Life Sciences to Present at the 37th Annual Roth Conference

Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule

Mar 14, 2025, 8:30 AM EDT - 1 year ago

Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule

Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial

Mar 4, 2025, 8:00 AM EST - 1 year ago

Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial

Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive Results for Nasal Anti-CD3 Therapy in Traumatic Brain Injury

Feb 27, 2025, 8:00 AM EST - 1 year ago

Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive Results for Nasal Anti-CD3 Therapy in Traumatic Brain Injury

Tiziana Life Sciences Announces Long Covid Study to Complete in Second Quarter

Feb 25, 2025, 8:00 AM EST - 1 year ago

Tiziana Life Sciences Announces Long Covid Study to Complete in Second Quarter

Tiziana Life Sciences Announces Agreement for Product Development Services with Renaissance Lakewood, LLC

Feb 21, 2025, 8:00 AM EST - 1 year ago

Tiziana Life Sciences Announces Agreement for Product Development Services with Renaissance Lakewood, LLC

Tiziana Life Sciences Announces Dosing of Additional Patients in Multiple Sclerosis Expanded Access Program

Feb 18, 2025, 8:00 AM EST - 1 year ago

Tiziana Life Sciences Announces Dosing of Additional Patients in Multiple Sclerosis Expanded Access Program

weather
weather Sep. 1 at 11:01 AM
$TLSA this must be the best short controlled stock in the market- they do want they want with it !
1 · Reply
JuggernautRaider
JuggernautRaider Aug. 31 at 9:49 PM
$TNXP $TLSA $IMRX $ALT 💊 🧠 🍱 🧬 🧘‍♂️
0 · Reply
WHATABOUTSTOCKS
WHATABOUTSTOCKS Aug. 31 at 8:25 PM
$TLSA $OKYO $ACUT = all you need to know ;) worst management.
0 · Reply
WHATABOUTSTOCKS
WHATABOUTSTOCKS Aug. 31 at 8:24 PM
$TLSA will probably delay again ... and again!
1 · Reply
123fabio
123fabio Aug. 31 at 7:05 PM
$TLSA I can't wait to get rid of $TLSA. It's hands down the worst stock I've held in my portfolio since 2021, a total and constant disappointment.
2 · Reply
rp6577
rp6577 Aug. 31 at 4:40 PM
$TLSA added. Very much expecting a rally into the phase 2a data. Positive readout will then send it. Big pharma asked to see data first. Very likely a partnership will arise for phase 3 $XBI
1 · Reply
JuggernautRaider
JuggernautRaider Aug. 28 at 2:05 PM
$IXHL oh baby kangaroo 🦘 $TLSA $INM $CGTX 😲
0 · Reply
weather
weather Aug. 28 at 6:31 AM
$TLSA Beware the shorters are back in town
2 · Reply
Iceman89
Iceman89 Aug. 26 at 8:23 PM
$TLSA Only about a month left!
1 · Reply
JuggernautRaider
JuggernautRaider Aug. 26 at 7:57 PM
$CGTX @Biopharma15 @Biotech_Beast @Biopharma2021 @Proposition_Joe @PeteyUSA Owe I agree. I’ve quietly accumulated 10K shares of CGTX. Also buying up $VYGR and $TLSA Sell $TSLA it is a DOG 🐶 ⚡️ 🪦
1 · Reply
JuggernautRaider
JuggernautRaider Aug. 26 at 5:19 PM
$NGEN $CGTX $TLSA $VYGR ooowwee! Tell me more 🐷 🧠 😋
2 · Reply
JuggernautRaider
JuggernautRaider Aug. 26 at 10:13 AM
$VYGR $TLSA $CGTX $ABOS these are my favorite four cognitive biotechs. Given I played football and have mild CTE and likely early onset Parkinson’s… i want to get more into neuroscience biotechs. Which am I missing? I keep studying the sector and these are my core four. Thanks! 🧠 💨 💊 💉 😯 🧫 😊 🦴 🍴 The BONESAW OF bioTech ~ thee Jay Sizzled 🎶
3 · Reply
weather
weather Aug. 26 at 8:15 AM
$TLSA Bio techs have been on a tear lately- but where is TLSA's tear ?
0 · Reply
LDCap
LDCap Aug. 25 at 4:20 PM
$TLSA Feels like the ATM is finally over. We should have around 8million in the bank. Enough to take us past Q1. Fingers crossed
0 · Reply
LDCap
LDCap Aug. 25 at 8:50 AM
$TLSA Nice poster presentation yesterday, keep moving Tizzy ☺️
0 · Reply
Housatonic1864
Housatonic1864 Aug. 24 at 3:48 PM
$TLSA Good News Ahead🫡
0 · Reply
rp6577
rp6577 Aug. 24 at 2:24 PM
$TLSA heating up 🔥 $XBI
1 · Reply
BioRich
BioRich Aug. 24 at 11:37 AM
$TLSA Tiziana Life Sciences Announces Poster Presentation on Phase 2a BANYAN Clinical Trial of Intranasal Foralumab at ALS Nexus 2026 https://ir.tizianalifesciences.com/news-releases/news-release-details/tiziana-life-sciences-announces-poster-presentation-phase-2a
0 · Reply
JuggernautRaider
JuggernautRaider Aug. 22 at 10:12 PM
$CGTX hmmm 🤔 🧠 🤕 🏈 💥 ♻️ 🚀 YES $TLSA $BMY $NVS 💯
1 · Reply
Iceman89
Iceman89 Aug. 21 at 6:39 PM
$TLSA CAR-T causes infertility. Foralumab has perfect safety profile.
1 · Reply
weather
weather Aug. 21 at 2:36 PM
$TLSA share doesnt respond well to good news
3 · Reply
JuggernautRaider
JuggernautRaider Aug. 21 at 10:18 AM
$MIST $TLSA $CGTX $GERN are four intriguing ones 🧐 Who knows though 🤷‍♂️
0 · Reply